Acclaro Medical has successfully closed a $23 million Series B funding round led by Accelmed Partners, with participation from existing investor 3E Bioventures Capital, to advance its pioneering 2910 nm fiber laser technology for aesthetic medicine. The funding comprises a $20 million investment from Accelmed and $3 million from 3E Bioventures Capital, marking a significant milestone for the Smithfield, Rhode Island-based medical technology company.
Revolutionary Laser Technology Addresses Unmet Clinical Needs
The company's flagship UltraClear fiber laser represents a breakthrough in aesthetic medicine as the first 2910 nm cold ablative fiber laser powered by proprietary 3DIntelliPulse™ technology. This innovative system treats multiple skin layers to help reverse signs of aging and gravity while delivering unparalleled clinical efficacy, superior patient experiences, unmatched versatility, and significantly improved safety for all skin types.
The technology addresses a critical gap in aesthetic medicine by providing safe treatment options for previously high-risk skin-of-color patients. Its precision-engineered capabilities enable practitioners to achieve transformative results with minimal downtime, reduced patient discomfort, and accelerated healing times.
Complementing UltraClear, the company's AuraLux laser leverages the same exclusive Cool Pulse™ technology to broaden accessibility for aesthetic providers while maintaining Acclaro's quality standards.
Strategic Growth and Market Expansion
"Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time," said Helen Fang, CEO and Co-founder of Acclaro Medical. "This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide."
The capital infusion will accelerate growth of the company's flagship products and expedite global market expansion while advancing development of new technologies in its pipeline. Shlomo Assa, President and co-founder of Acclaro Medical, emphasized the funding's role in expanding both global and domestic footprints while accelerating product development and team expansion.
Industry Recognition and Investment Rationale
Daniel Cohen, Accelmed's venture partner with extensive experience in successful Medtech and Biotech investments over the past 20 years, highlighted the transformative potential of Acclaro's technology. "Acclaro's unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device," Cohen stated.
The investment reflects confidence in Acclaro's mission to revolutionize the aesthetic industry through innovative, patient-centered skin health solutions. Founded in 2018 by industry experts, the company has developed proprietary 3DMIRACLE™ and Laser Coring™ skin rejuvenation treatments valued for delivering exceptional aesthetic results with high patient comfort, rapid healing, and optimal safety across all skin types.
Financial Partnership and Future Outlook
Accelmed Partners, which manages over $630 million of equity capital, brings decades of operational and financial expertise to support Acclaro's strategic plans. The healthcare technology investment firm is renowned for its private equity approach in a sector traditionally dominated by venture and early-stage growth firms.
The partnership positions Acclaro Medical to execute its strategic vision of revolutionizing the aesthetic industry while cementing its position as a leader in innovative skin health solutions. The company's technology platform addresses unmet medical, aesthetic, and surgical practice needs through its commitment to innovation and boundary-pushing development.
